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ABSTRACT

Alzheimer's disease (AD) distresses the lives of millions of people around the
world. Its costs were estimated to be at least l 00 billion dollars each year (Fill it,
2000). And so far, no cure has been found to stop or slow the progression of the
disease. Senile plaques and neurofibrillary tangles are considered to be central in
the pathogenesis of AD. The plaques are mainly composed of aggregations of
amyloid

p (AB) peptides, which are generated

upon the sequential cleavage of the

larger amyloid precursor protein (APP) first by the enzyme P-secretase, and then
by the enzyme y-secretase. These plaques are one of the main targets being
explored for newer therapeutic interventions in AD. The transcription factor
specificity protein 1 (Sp 1) is associated with the pathology of AD, as it was found
to be involved in the transcription of APP and beta site APP cleaving enzyme l
(BACE 1) (Christensen et al., 2004, Basha et al., 2005, Santpere et al., 2006).
Tolfenamic acid is an NSAID that was reported to lower Sp 1 levels (Abdelrahim
et al. , 2006). Accordingly, this study was designed to examine the capability of
tolfenamic acid to decrease the levels of the transcription factor Sp 1, and
therefore, other AD involved proteins and peptides like APP and

AB

within

animals' brains. Consequently, the drug was administered to C57BL/6 mice and
Hartley guinea pigs. Different doses of the drug were tried to find the dosage
range where efficacy is achieved. Animals also were sacrificed at different time
points, in order to study the drug effects over the time course of the study. Data
showed that tolfenamic acid was able to lower SP l, APP and AP in the brains of
animal models in a time dependent manner, and within certain doses. These

studies demonstrate that tolfenamic acid 1s a potential candidate for further
development as a treatment for AD .

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to my advisor, Dr. Nasser Zawia,
who accepted me into his laboratory, and gave me this opportunity along with all
the support, knowledge, and guidance I needed to work on this project. I want to
extend my appreciation to my colleagues at Dr. Zawia's lab, and our collaborators,
who have greatly contributed to this study at many occasions. I also want to thank
the Fulbright Foreign Student Scholarship program for generously funding my
study and stay in the United States throughout the past two years and a half. And
fi nally, J am extremely grateful to my family and my friends , for their precious
hel p and support.

IV

TABLE OF CONTENTS

Page
Abstract. ... .... ... ...................... . ........ . ..... .. ... . ................... ........ ii
Acknowledgements ... .. ........ . ... ...... .... ................................. ..... .. iv
Table of contents ................. . ... .......... .. .............. . ....... . ..... ......... v
List of Tables .............. ............................................. . ........ . ..... vi
List of Figures ............................... ........ ....... .. . . .. ... . ............. .. . vii
1.0 Introduction ......... ............................................................... 1
1.1 Background and significance . . .......... .... .. ....... . ............. ... I
1.2 Objectives .. . . . .. . ...................................................... ... 10
1.3 Experimental design ...... ..... ... ..... ............... .. ........ . ....... . 13
2.0 Materials and Methods ......................... .. .......... ... ...... ............. 14
3.0 Results .............................................................................. 20
3.1 A pilot study in male C57BL/6 mice .................... . ............ 20
3.2 A pilot study in male Hartley guinea pigs ........................... 25
3.3 A study in female mice ....... .... ................ ... ................... 25
3.4 A time and dose range finding study ................................. 34
4.0 Discussion .. ...... .... .. ........ .. ..... .... .. . ............ ... ... ......... .... ... .. .52
5.0 Conclusion . .. ............... ... .......... . .. . .... .. . . .. ... .... . . . ........... ..... . 58
Bibliography ........................................................................... 59

v

LIST OF TABLES

Page

Table 1.

A Summary of the effect of daily dosing with various doses
of tolfenamic acid on SPI, APP and Ap ............... .46

VI

LIST OF FIGURES

Page
Figure: 1.

A proposed transcriptional pathway for brain amyloid
plaque formation ..... . ... . .. . .. . . ... . ... . .. . ........ ... . ..... ... . . .. 5

Figure: 2.

Proposed down-regulation of the APP gene by
tolfenamic acid ...................................................... 11

Figure: 3.

APP and SP 1 levels in mice treated with tolfenamic acid ..... 21

Figure: 4 .

AP ( 1-40) levels in male mice treated with tolfenamic acid ... 23

Figure: 5.

Changes in APP levels in guinea pigs treated with
tolfenamic acid ......... ... ...... . .......... . ... .... . .. . .......... .. . 26

Figure: 6.

AP (1-42) levels in guinea pigs exposed to tolfenamic acid ... 28

Figure: 7.

APP levels in the cerebral cortex of female mice treated
with various doses oftolfenamic acid ..... . ... . ... . . ... ... . . .. . . 30

Figure: 8.

Temporal changes in APP levels in cerebral cortex of
female mice treated with tolfenamic acid .. .... .. .......... ..... 32

Figure: 9.

APP levels in the cerebral cortex of mice treated with
various doses oftolfenamic acid ... ... ... . . . ............ . .... . ... 36

Figure: 10.

Temporal changes in APP levels in the cerebral cortex of
mice treated with tolfenamic acid ...... . .......................... 38

Figure : 11 .

SP 1 levels in the cerebral cortex of mice treated with
different doses oftolfenamic acid ................................. 40

VII

Page

Figure: 12.

AP (1-40) levels in the cerebral cortex of mice treated
with various doses of tolfenamic acid ........................... .42

Figure: 13.

AP (1-42) levels in the cerebral cortex of mice treated with
various doses of tolfenamic acid ............ .................... .44

Figure: 14.

Temporal changes in

AP (1-40) levels in the cerebral

cortex of mice treated with tolfenamic acid .................... .48
Figure: 15.

Temporal changes in

AP (1-42) levels in the cerebral

cortex of mice treated with tolfenamic acid ...................... 50

viii

1.0 Introduction

1.1 Background and significance

Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by
dementia evolving till death. During the course of the disease, memory, cognitive
performance, and other daily activities are all impaired . In 2000, the number of
AD cases in the US was about 4.5 million (Hebert et al., 2003), this number has
reached 5.2 million in 2008 (Alzheimer's Association, 2008), it was estimated it
would grow up to 13.2 million in 2050 (Hebert et al., 2003). In addition,
Brookmeyer et al. (2007) predicted that that the number of AD cases around the
world grow from 26.6 million in 2006 to 106.8 million in 2050. Annual ADassociated costs were estimated to be at least 100 billion dollars solely in the US
(Fi llit, 2000). So far, no cure was found for AD, and all available medications are
prescribed for symptomatic or adjuvant therapy.

The

characteristic

neuropathological

deposits

identified

in

AD

are

the

extracellular Amyloid beta (AP) plaques and intracellular tau tangles (Terry et al. ,
1964; Thal et al., 2004; Goedert and Spillantini, 2006). Alois Alzheimer described
those neuritic plaques and neurofibrillary tangles more than a hundred years ago
(Goedert and Spillantini, 2006). Since then, numerous studies have explored these
plaques and tangles (Terry et al., 1964; Evin and Weidemann, 2002; Thal et al.,
2004; Goedert and Spillantini, 2006). Under the electron microscope, these

deposits display abnormal filaments (Terry et al., 1964). A recent study confirmed
these findings , as extensive AP depositions were found in the neocortex and
caudate nuclei of AD patients, and these deposits were more abundant in AD than
in healthy controls; dementia with Lewy bodies; frontotemporal dementia; and
mild cognitive impairment (Rowe et al., 2007).

The main component of AD plaques is the AP peptide. It is 39-43 amino acids
long, and is generated by cleavage of the amyloid precursor protein (APP) (Haass
et al., 1991 ; Urbane et al., 1999). This amyloidogenic pathway involves cleavage
of APP by the enzyme P-secretase, followed by y-secretase. The produced AP is
normally secreted, but also can accumulate resulting in formation of insoluble
aggregates (Shoji et al., 1992; Urbane et al., 1999). Two forms of AP can be
generated, AP4o and AP 42 , the difference between the two is not only in the
number of amino acids in their composition, but also AP42 was found to be more
aggregative, and it was proposed that AP42 triggers plaque formation in AD
(Naslund et al., 2000). Furthermore, Shoji et al. (1992) suggest that formation of
the insoluble AP depositions depends on the rate of AP production and the rate of
its elimination. Accordingly, the amyloid hypothesis of AD was developed,
suggesting that amyloid plaque aggregates formed by the amyloidogenic
breakdown of APP cause the neurodegeneration and dementia seen in AD
(Selkoe, 1993; Hardy and Selkoe, 2002). On the other hand, APP also can be
processed by a non-amyloidogenic pathway, where it is cleaved within the AP
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region, resulting in secreted products that do not form deposits (Shoji et al.,
1992). This occurs following APP cleavage by the enzyme a-secretase.

The specificity protein 1 (Sp 1) is a transcription factor involved in the pathology
of AD (Zawia and Basha, 2005; Basha et al., 2005; Santpere et al., 2006). Sp 1
acts as a co-activator in the process of the transcription of APP (Docagne et al.,
2004). Previous studies have shown that the APP promoter includes several Sp 1
binding sites (Lukiw et al., 1994; Hoffman and Chernak, 1995; Querfurth et al.,
1999; Zawia and Basha, 2005). Furthermore, Sp 1 greatly regulates the expression
of beta site APP cleaving enzyme 1 (BACE 1) (Christensen et al., 2004). BACEI
is the main form of P-secretase that cleaves APP to generate AP (Cai et al., 2001).
Christensen et al. (2004) found that overexpression of SP 1 increases BACE 1
promoter activity, while the decline in Sp 1 protein reduces transcription of the
BACE 1 gene. Likewise, silencing the Sp 1 gene dramatically reduces APP
promoter activity (Basha et al., 2005). In addition, in vivo immunohistochemical
results have shown that Sp I, APP, and AP co-localize in brain neurons (Brock et
al., 2008). In addition, Sp I regulates the expression of phosphorylated tau
(Heicklen-Klein and Ginzburg, 2000). The buildup of hyper-phosphorylated tau
results in the formation of the pathogenic tangles found in AD and some other
neurodegenerative disorders like Pick's disease (Santpere et al ., 2006).

Early-onset familial AD (FAD) compromises 5-10% of all AD cases. The
majority of FAD is related to mutations on genes encoding the presenilin (PS)
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membrane proteins, PS-1 , PS-2 (Czech et al., 2000). Presenilin mutations increase
production of AP 42 from APP, and increased AP 42 levels were observed in the
blood and brains of FAD patients with presenilin abnormalities (Czech et al.,
2000). In addition, neurons lacking the PS- I gene fail to produce AP peptides (De
Strooper et al. , 1998; Naruse et al., 1998). Consequently, PS-I was found to be
related to the activity of the enzyme y-secretase (De Strooper et al. , 1998;
Shimojo et al., 2007). AP and its aggregates also were found to cause synaptic
dysfunction and loss (Mattson, 1997; Takahashi , 2002; Fein et al., 2008).
Collectively, these findings confirm the involvement of AP in the pathology of
AD. The role of Spl , APP and AP in plaque formation and AD is illustrated in
Fig. I .

4

Figure 1. A proposed transcriptional pathway for brain amyloid plaque formation.
Sp I binds to the promoter region of the APP gene, resulting in enhancement of
APP transcription and tarnslation. APP is then cleaved first by the enzyme
secretase, and then by y-secretase to produce

Ap, which

can aggregate forming

the amyloid plaques that contribute to the pathology of AD.
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To date, no drug has been found to stop the progression of AD. All available
medications are prescribed as symptomatic or adjuvant therapy. FDA approved
drugs for AD include acetylcholinesterase inhibitors and the N-methyl-Daspatarte (NMDA) receptor antagonist memantine. The rational for using
cholinesterase inhibitors in AD is based on the cholinergic hypothesis, in which
the decline in cholinergic function with age was proposed to contribute to the
cognitive dysfunction in AD (Bartus et al., 1982). Accordingly, cholinesterase
inhibitors like donepezil, rivastigmine, and galantamine are currently prescribed
for mild to moderate AD, and have produced improvement in disease symptoms
(Francis et al., 1999). The other drug approved for treating AD is memantine, an
NMDA receptor antagonist that blocks the excitotoxicity effects of glutamine, and
is used in moderate to severe cases of AD (Reisberg et al., 2003). Improved AD
symptoms were observed with memantine administration (Mobius . and StOffler,
2003; Reisberg et al., 2003). Additionally, antipsychotics and antidepressants are
sometimes prescribed to manage corresponding ailments that can arise in AD
patients (Lesser and Hughes, 2006). Non-prescription medications also are used
for their anti-oxidant properties like the vitamins C and E, however, their use in
AD is controversial (Boothby and Doering, 2005).

Considering the large and increasing number of AD cases and the devastating
course of the disease, there is a great need for developing drugs that target critical
pathologic mechanisms in AD. Continuing research revealing additional insights
into the pathogenesis and molecular mechanisms behind AD has created more
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hope for disease modifying therapies, rather than merely symptomatic treatment.
New mechanisms are under investigation for the design of new drugs for AD.
Many approaches targeting the pathological plaques of AD are being examined,
particularly those exploring different factors in the production, secretion, and
degradation of AP peptides (Roberson and Mucke, 2006).

Epidemiological studies have demonstrated that chronic exposure to non-steroidal
anti-inflammatory drugs (NSAIDs) has a positive effect on AD. NSAIDs exert
their anti -inflammatory effects by blocking the cyclooxygenase (COX) mediated
production of prostaglandins. Various mechanisms have been suggested for
NSAIDs' role in AD. According to a meta-analysis of different studies on
NSAIDs in AD, it was found that NSAIDs exposure reduced the risk for AD
development (Szekely et al., 2004). However, these effects were not consistent
among all NSAIDs, and in all studies. It was proposed that NSAIDs decrease
BACE I levels as they activate the peroxisome proliferator-activated receptor-y
(PPARy) and that would be how they exert their protective effect in AD (Sastre et
al., 2006). Other studies suggested that NSAIDs act by affecting y-secretase
activity, resulting in the decrease of AP 42 production, apart from their COX
inhibition activity (Weggen et al., 2001; Eriksen et al., 2003).

Tolfenamic acid is an NSAID currently used to treat migraine symptoms m
humans in Europe, and for pain management in veterinary medicine in the US.
Recently, tolfenamic acid also was found to decrease the levels of transcription

8

factors Sp 1, Sp3, and Sp4 in pancreatic tumors, and thus inhibit their growth
(Abdelrahim et al., 2006). Since Sp 1 is associated with the pathology of AD
(Basha et al., 2005; Santpere et al., 2006), particularly through APP transcription
coactivation (Docagne et al., 2004), and

regulating BACE 1 expression

(Christensen et al., 2004), this study was designed to examine the potential of
tolfenamic acid as a new therapeutic intervention for AD.

9

1.2 Objectives

Previous studies from our lab have shown that the transcription factor Spl is
associated with the pathology of AD. Increased APP mRNA expression later in
life following prior lead exposure early in life was coupled with increased Sp I
activity (Basha et al., 2005, Wu et al. 2008). Furthermore, recently published in
vivo immunohistochemical results have confirmed the formerly established link
between Sp I and APP, and have proposed that AP is more likely to be found in
cerebral cortex and hippocampal areas with higher Sp I levels (Brock et al., 2008).
This study was designed to examine Sp I as a target involved in a possible
therapeutic intervention of Alzheimer's disease. Tolfenamic acid is an NSAID
found to lower Sp I levels, and subsequently inhibit the growth and angiogenesis
of pancreatic tumors (Abdelrahim et al, 2006). Accordingly, this research work
was conducted to investigate the ability of tolfenamic acid to lower AD associated
proteins like APP and AP through its action on Spl, as illustrated in Fig. 2.

Specific aims

1. Exami ne the ability of tolfenamic acid to reduce APP and AP protein levels in
the brains of wild type animal models exposed to the drug.

2. Test the ability of tolfenamic acid to decrease levels of the transcription factor
Sp I with in the brains of animal models dosed with tolfenamic acid.

10

Figure 2. Proposed down-regulation of the APP gene by tolfenamic acid.
Tolfenamic acid promotes the degradation of the transcription factor Sp 1. Sp l
decline results in a decrease in APP transcription, and thus lowers APP and AP
levels. This would be expected to diminish amyloid plaque pathology.
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1.3 Experimental design

C57BL/6 mice were exposed to different doses of tolfenamic acid or vehicle in
order to examine whether the drug can affect the fol lowing proteins: APP, SP 1,
and AP in comparison to vehicle. At first, a pilot study was conducted using a few
doses of tolfenamic acid in a small number of animals. The study was repeated
with a wide but safe selection of doses of tolfenamic acid, in order to examine the
dose range where the drug was affecting AD related proteins. Moreover, animals
were sacrificed at different time points during the study, in order to examine the
changes in those proteins over time. In addition, tolfenamic acid also was tested in
Hartley guinea pigs, as they have been suggested to represent a better animal
model for studying pathological changes related to AD, since their AP peptides
are identical to the ones found in humans (Beck et al. , 2003). Following each
study, the brains of these animals were tested for changes in the levels of their
APP, SP 1, and AP peptides by the proper analytical techniques.

13
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2.0 Materials and methods

Materials and instruments

Most chemicals and reagents were purchased form Thermo Fisher Scientific Inc.
(Rockford, IL) unless otherwise noted. Tolfenamic acid was purchased from LKT
Laboratories Inc. (St. Paul , MN). Micro BCA Protein Assay Kit and Super signal
Ultra from Pierce (Rockford, IL). Nitrocellulose transfer membranes from BioRad Laboratories (Hercules, CA). PVDF transfer membranes from GE Osmonics
Labstore (Minnetonka, Mn). ECL Plus Western Blotting Detection Reagents,
ImageQuant™ 5.2 software, and the Typhoon™ Variable Mode Imager from GE
Healthcare Bio-Sciences Corporation. (Piscataway, NJ). KODAK Image Station
2000MM from Eastman Kodak (Wood Dale, IL). Primary antibodies against
APP, actin, and GAPDH were from Sigma Chemical Co. (St. Louis, MO).
Additionally, APP primary antibody was purchased from Millipore Corporation.
(B illerica, MA). SPI antibody was obtained from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA). Human AP (1-40) and (1-42) ELISA assay kits were from
Imm uno-Biological Laboratories (Gunma, Japan) .

Animal Exposure

Mice (C57B L/6 strain) were either bred in-house or obtained from Charles River
Laboratories (Shrewsbury, MA) or Jackson Laboratory (Bar Harbor, ME). Guinea
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pigs

(Hartley

strain)

were

purchased

from

Charles

River

Laboratories

(Shrewsbury, MA). Animals were housed in rooms designated for each species
within the animal facility at URI.

Mice of the C57BL/6 strain were used as they have already been employed for
AD research. Guinea pig

A~

is identical to that of humans (Beck et al., 2003;

Anderson et al.,2005; Du et al., 2007), and like humans, guinea pigs were found
to be one of the animal models that express neuritic plaques in vivo, while
plaques can not be found in smaller animals like mice and rats (Beck et al., 2003).
However, no plaques were seen within the brains of 10 guinea pigs with ages up
to 10 years old (Rossner, personal communication, December 22, 2007). The fact
that these animals express structures similar to neutritic plaques found in human
brains was first cited in a German source that dates back to 1910, nevertheless,
this book did not provide any images of those plaques (Previous source; Beck et
al., 1997). Since then, numerous articles have mentioned that plaques are
naturally present within the guinea pig brain, while a thorough literature review
revealed no further information or images supporting such statements.

Animals were exposed to tolfenamic acid prepared in corn oil through gavage
(oral dose) for 4-5 weeks. Animals were divided into groups of 2-6 animals in
each, including a control group receiving corn oil; and experimental groups
receiving either 1, 5, I 0, 25, 50, or 150 mg/kg body weight doses of tolfenamic
acid in corn oil. Cremophor was used as the solvent for the tolfenamic acid
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fo rmulation administered to guinea pigs, since the 50 mg/kg dose could not be
ach ieved in a small volume of corn oil , as the animals were I 0 times the weight of
mice. The standard guidelines and the protocol approved by IACUC were
fo ll owed for animal handling. Animals were euthanized by C02 asphyxiation in a
speciall y designed canister for that purpose. They were left in the canister to be
rendered unconscious and dead. The dead animals also were decapitated to
eliminate any uncertainty. This method is consistent with the recommendations of
the Panel on Euthanasia of the American Veterinary Association. The brains of
these animals were

isolated , and

the various

regions; cerebral

cortex,

hippocampus, cerebellum and brain stem; were separated on dry ice and stored at
-80°C. The effect of tolfenamic acid on APP and AP peptides was examined
within the cerebral cortices of brain samples.

Accord ingly, and due to study requirements, four separate and independent
animal ex periments were conducted. First, a small number of 2 months old male
C57BL/6 mice were dosed every other day (i .e. 3 times a week), with either corn
oil, I 0, 50, or 150 mg/kg tolfenamic acid in corn oil for 5 weeks. Ln the following
study, l month old male Hartley guinea pigs were dosed every other day with 50
mg/kg tol fe namic acid solution in cremophor or vehicle for 4 weeks. The third
experiment conducted included dosing of female C57BL/6 mice with either 5, 10,
or 25, mg/kg tolfenamic acid in corn oil, or vehicle every other day for four
weeks. And finally tolfenamic acid was administered dail y to male C57BL/6 mice
in one of the following doses 0 (vehicle) 1, 5, 10, 25 , or 50 mg/kg. All tolfenamic
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acid formulations for the first three studies were kindly provided by Dr. Maen
Abdelrahim (Anderson Cancer Center, Orlando Cancer Research Institute,
Orlando, FL). Guinea pig brains were kindly donated by Dr. Thomas Mather
(Un iversity of Rhode Island, Kingston, RI), to conduct Western blot analyses and
ELISA assays necessary for early optimization of experimental conditions.
Female C57BL/6 mice were kindly given by Dr. Angela Slitt (University of
Rhode Island, Kingston, RI).

Protein extraction

Approximately 0.1 gm of cerebral cortex tissue was homogenized with 500 µI of
the RIPA lysis buffer (10 mM Tris-HCI [pH 7.4], 150 mM NaCl, 1% Triton X100, 0.1 SOS , 1 mM EDTA). The homogenate was then centrifuged at 10,000
rpm for I 0 minutes at 4°C, and the supernatant was collected. Protein
concentration was determined using the Micro BCA Protein Assay Kit. Extracts
were stored at -80°C until used.

Western Blot Analysis

Western blot analysis was performed to observe the changes in the levels of SP 1,
APP, and the housekeeping proteins actin and GAPDH among control and
treatment tissues. The method mentioned in previous studies was followed
(Atwood et al., 1998; Nunomura et al., 1999; Atkins et al., 2003). In brief,
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samples were loaded onto 8% gels (5.35 H2 0, 2.5 ml of 1.5 M Tris-HCI, [pH 8.8],
100 µI of 10% SDS, 2 ml of 40% Acrylamide/Bis, 50 µI of 10% Amonium
Persulfate, and 5 µI TEMED). The samples were then run for about 1-2 hours at
20-30 mA, transferred to nitrocellulose or PVDF membranes, fixed, and blocked
with 5% non-fat milk overnight. After that, the membranes were incubated with
the specific primary antibody for 1-2 hours at room temperature, then with the
secondary antibody for 1 hour at room temperature, and finally with ECL plus
reagent for 1 minute. The florescence of Western blot bands was detected using
the Typhoon™ Variable Mode Imager. In some experiments, Super signal Ultra
was used to detect chemilumescence where the membranes were incubated with
the substrate for 3-5 minutes and the signal was detected using the KODAK
Image Station 2000MM. Quantitative assay of the bands was performed using
ImageQuant™ 5.2 software.

ELISA

A~

(1-40) and AP (1-42) Assay

The levels of AP were measured using human AP ( 1-40) and ( 1-42) assay kits.
These kits are solid-phase sandwich ELISA with two kinds of highly specific
antibodies, which are I 00% cross reactive with mouse AP (1-40), and 70% cross
reactive with mouse AP (1-42). The assay was conducted as mentioned within the
manufacturer's instructions (Immuno-Biological Laboratories, Gunma, Japan) and
Morishima-Kawashima et al. (2000) with minor modifications. I 00 µg of protein
samples in 100 µI of EIA buffer and assay standards were added to a 96-well
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plates pre-coated with anti-human AP mouse IgG MoAb. The plates were
incubated overnight at 4°C. Plates were washed using the 40X diluted wash buffer
supplied with the kit (0.05% Tween20 in phosphate buffer) for 7 times,
afterwards, 100 µL of labeled antibody were added to the samples and standards,
and they were incubated for one hour at 4°C. The plates were washed again 9
times, and then 100 µL of tetramethylbenzidine were added as a coloring agent.
The plates were incubated in the dark for 30 minutes at room temperature. Finally
100 µL of 1N H 2 S04 were added to stop the reaction, and absorbance was
measured at 450 nm using a UV/Vis Spectrometer. The concentration of AP in
unknown samples was obtained as pg per mg protein after plotting the absorbance
of standards against the standard concentrations.

Statistical Analysis

Data were represented as the mean ± the standard error of the mean (SEM).
Statistical analysis was performed using two-tailed Student's I-test, and results
marked with an asterisk were significantly different from the control group

(p<0.05).
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3.0 Results

The transcription factor Sp I is an essential factor within the pathology of AD
(Christensen et al., 2004, Basha et al. , 2005 , Santpere et al. , 2006). Tolfenamic
acid was found to stimulate the degradation of Sp 1 in pancreatic tumor cells
(A bdelrahim et al., 2006). Accordingly, the effects of tolfenamic acid
administration on proteins related to AD pathology were examined in animal
models. Four studies were conducted to observe changes in APP and

A~

levels,

protei ns that are affiliated with the neurodegeneration in AD according to the
amyloid hypothesis. Within these studies, different doses of tolfenamic acid were
tested and compared to the vehicle controls. The dose range effects were
examined in samples obtained from the animals ' cerebral cortexes.

3.1 A pilot study in male C57BL/6 mice

Treatment with 10 and 50 mg/kg of tolfenamic acid every other day for five
weeks significantly reduced APP protein levels in the cerebral cortex of male
mice when compared to controls (student's t test p <0.05) (Fig. 3A). SP I protein
leve ls were lower in I 0 mg/kg treated animals as demonstrated by Western blot
analys is (Fig.3B).

A~

( 1-40) protein levels also were significantly reduced within

the cerebral cortex of the same treatment groups in comparison to controls
(student' s t test p <0.05) (Fig. 4).
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Figure 3. APP and SP! levels in mice treated with tolfenamic acid. Animals were
two months of age at the beginning of the study. They were given 0, l 0, or 50
mg/kg tolfenamic acid (n=3 in each dose group). Doses were administered three
times a week for 5 weeks by oral gavage. (A) APP levels in cerebral cortex
samples from control and tolfenamic acid treated animals. APP protein levels
were expressed as a ratio of the housekeeping protein GAPDH as measured by
Western blot analysis, described in the methods section. Values are shown as the
mean ± SEM. Results for treatment animals (n=6) were pooled together as their
values compared to each other were not statistically significant. The"*" indicates
that values are significantly different from control, as determined by a student's ttest (p<0.05). (B) SPl Western blot results of samples from mouse brain extracts
from controls and animals treated every other day with 10 mg/kg tolfenamic acid
for 5 weeks.
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Figure 4. AP (1-40) levels in male mice treated with tolfenamic acid. Animals
were two months of age at the beginning of the study. They were given vehicle,
10, or 50 mg/kg tolfenamic acid (n=3 in each dose group). Doses were
ad ministered three times a week for 5 weeks by oral gavage. AP levels were
measured in pg/mg protein using an ELISA assay as described in the methods
section. Values shown are the mean ± SEM. Results for treatment animals (n=6)
were pooled together as their values compared to each other were not statistically
significant. The " *" indicates that values are significantly different from control,
as determined by a student' s t-test (p< 0.05).
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3.2 A pilot study in male Hartley guinea pigs

In guinea pigs 50 mg/kg tolfenamic acid in cremophor decreased APP cerebral
cortex levels by thirty percent in comparison to controls as determined by
Western blot analysis, following 4 weeks of every other day dosing (n=3). This
change was significant (p=0.01) according to student's I-test (Fig. 5).

A~

(l-42)

displayed a lowering trend, but it was not statistically significant according to
student's I-test (p= 0.23) (Fig. 6).

3.3 A study in female mice

After tolfenamic acid was administered to female mice, three times a week, for
four weeks, cerebral cortex APP levels were significantly lowered with l 0 and 25
mg/kg doses by 52.18% and 40.58% respectively (student's I-test p<0.05). APP
also was lower within the cerebral cortex samples obtained from animals dosed
with 5 mg/kg, however, this change was not statistically significant as determined
by student's I-test (p=0.11) (Fig. 7).

On days 4 and 8, the APP/GAPDH ratio was not changed. However, on day 16
there was a clear downward trend (23%). By day 29, 10 mg/kg tolfenamic acid
decreased APP levels by 52.18% as a percentage change from control, which was
statistically significant, student's I test p =0.0 I (Fig. 8).
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Figure 5. Changes in APP levels in guinea pigs treated with tolfenamic acid.
Animals' age was one month at the beginning of the study. They were given
either vehicle or 50 mg/kg tolfenamic acid orally three times a week for 4 weeks .
APP protein levels in cerebral cortex samples were expressed as a ratio of the
housekeeping protein GAPDH as measured by Western blot analysis described in
the methods section. Values shown are the mean± SEM (n=3). The "*" indicates
that the change is statistically significant, as determined by student's t-test
(p=0.01).
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Figure 6.

A~

(1-42) levels in guinea pigs exposed to tolfenamic acid. Animals

were two months old at the beginning of the study. They were dosed with either
vehicle or 50 mg/kg tolfenamic acid orally three times a week for 4 weeks.

A~

(I-

42) levels in cerebral cortex protein samples were measured as pg/mg protein by
an ELISA assay as described in the methods section. Values shown are the mean
± SEM (n=4).
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Figure 7. APP levels in the cerebral cortex of female mice treated with various
doses of tolfenamic acid. Animals' age was two-three months at the beginning of
the study. Vehicle, 5, 10, or 25 mg/kg tolfenamic acid were administered three
times a week by oral gavage for four weeks. APP protein levels in cerebral cortex
samples were expressed as the ratio of the housekeeping protein GAPDH, as
measured by Western blot analysis described in the methods section. Values
shown are the mean ± SEM. The number of animals in each group was: control
(n=2); 5 mg/kg (n=3); 10 mg/kg (n=5); and 25 mg/kg (n=2). The "*" indicates
that values are significantly different from control, as determined by a student's!test (p< 0.05).
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Figure 8. Temporal changes in APP levels in cerebral cortex of female mice
treated with tolfenamic acid. Animals ' age was two months at the beginning of
the study. They were given either vehicle or 10 mg/kg tolfenamic acid three times
a week by oral gavage. Control and treatment animals were sacrificed on day 4, 8,
and 29 after the beginning of the study. Results are expressed as the percentage of
APP/GAPDH change from each group ' s control as obtained by Western blot
analys is described in the methods section. The number of animals in each group:
day 4 control (n=2), treatment (n=4); day 8 control (n=2), treatment (n=4); day 29
control (n=2), treatment (n=5) . The " *" indicates that values are significantly
different from control, as determined by a student' s t-test (p<0.05).
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3.4 A time and dose range finding study

To determine the range of effective doses, tolfenamic acid was administered daily
at the following concentrations: 1, 5, l 0, 25, and 50 mg/kg. It was observed that
cerebral cortex APP levels were significantly lowered (student's t-test p=0.04) by
18 .52% with the 5 mg/kg dose. The remaining four doses resulted in no change
(Fig. 9).

Moreover, changes in APP with the 5 mg/kg treatment were examined at different
time points. On days 4 and 8, there were non-significant fluctuations in APP
levels. However, there was as a nearly significant 20% lowering trend (p =0.13) of
APP levels 8 days following daily tolfenamic acid administration. On day 16,
tolfenamic acid significantly decreased APP levels by 18.52%, student's t test
p=0.04 (Fig. 10).

Changes in SPJ levels also varied in response to different doses of tolfenamic
acid (Fig. 11 ). SP I protein was significantly less than control in the cerebral
cortex of animals treated daily with 5 and l 0 mg/kg tolfenamic acid, with the
percentages of change from control being 57 .65%, and 30.13% respectively
(Student's t-test p=0.02, p=0.05).

Changes in levels of

AP

(1-40) at day 16 following daily doses of 1, 5, 25 , 50

mg/kg tolfenamic acid compared to controls are shown in Fig. 12. Treatment
I
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animals' AP ( 1-40) was lower than controls by the following percentages; 24.32%
with the 1 mg/kg dose (p=O .O1); 14.27% with 5 mg/kg (p=0.06); 25.29% with 25
mg/kg (p =0.02); and 21.61 % with 50 mg/kg (p= 0.05). AP (1-42) changes can be
'
I

examined from Fig. 13, AP ( 1-42) levels were significantly lower than controls by

I

the following percentages; 32.81 % with the 1 mg/kg dose (p=0.05) 68 .2% with 5
mg/kg (p =0.02); 32.96% with 25 mg/kg (p=0.02); and 29.45% with 50 mg/kg
(p=0.0004).
'
1,
!

The overall changes in SP 1, APP, and AP following daily dosing with different
doses of tolfenamic acid for 15 days are summarized in Table 1. Accordingly,
higher doses of tolfenamic acid and a dose as low as 1 mg/kg administered daily
did not alter SPl (Fig. 11), but still had a lowering effect on AP (Fig. 12, Fig. 13).

The changes occurring in AP (1-40) during the time course of the 5 mg/kg daily
treatment are demonstrated in Fig. 14. Only on day 16 post treatment, AP ( 1-40)
levels dropped by 14.06% (p=0.06). The changes in AP (1-42) were examined
following daily 5 mg/kg administration of tolfenamic acid for 15 days (Fig. 15).
Exclusively on day 16 a statistically significant change could be observed with 68.2% percentage change in AP (1-42) (p=0.02).
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Figure 9. APP levels in the cerebral cortex of mice treated with various doses of
tolfenamic acid. Animals' age was 3 months at the beginning of the study.
Animals were dosed with 0, 1, 5, I 0, 25, or 50 mg/kg tolfenamic acid by oral
gavage daily for 15 days. APP levels detected by Western blot are shown as a
ratio of the levels of the housekeeping protein actin. Values shown are the mean±
SEM. The number of animals in each group: control n=2; 1 mg/kg n=3; 5 mg/kg
n=3; 10 mg/kg n=4; 25 mg/kg n=4; 50 mg/kg n=3. The"*" indicates that values
are significantly different from controls, as determined by a student's t-test
(p<0.05).
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Figure I 0. Temporal changes in APP levels in the cerebral cortex of mice treated

1

with tolfenamic acid. Animals ' age was 3 months at the beginning of the study.
Vehicle or 5 mg/kg tolfenamic acid were administered daily, and animals were
sacrificed at days 4, 8, and 16 following commencement of the treatment. Results
are expressed as the percentage of APP/actin change from each group ' s controls
as obtained by the Western blot analysis described in the methods section. The
number of animals in each group, day 4 control n=4, treatment n= S; day 8 control
n=3, treatment n=3 ; day 16 control n=2, treatment n=3. The " *" indicates that
values are significantly different from control , as determined by a student' s t-test

(p<0. 05 ).
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Figure 11. SP I levels in the cerebral cortex of mice treated with different doses of

I

to lfe namic acid. Animals ' age was 3 months at the beginning of the study. They
were treated with 0, I , 5, 10, 25 , or 50 mg/kg tolfenamic acid daily by oral gavage
for 15 days. SP I protein levels were expressed as a ratio of the housekeeping
protein actin measured by Western blot analysis, described in the methods
section. Values shown are the mean ± SEM. The number of animals in each
gro up : control n=2 ; 1 mg/kg n=4; 5 mg/kg n=3; 10 mg/kg n=4; 25 mg/kg n=5 ; 50
mg/kg n=5. The " *" indicates that values are significantly different from control ,
as determined by a student' s t-test (p<0.05).
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Figure 12. AP (1-40) levels in the cerebral cortex of mice treated with various
doses of tolfenamic acid. Animals were 3 months at the beginning of the study.
They were given one of the following doses of tolfenamic acid 0, 1, 5, 25 , 50
mg/kg. The drug was administered daily by oral gavage for 15 days. AP (1-40)
levels were measured by an ELISA assay according to the procedures illustrated
in the methods section. Results shown are the mean ± SEM. The number of
animals in each group, control n=3; lmg/kg n=4; 5 mg/kg n=4; 25 mg/kg n=5;
and 50 mg/kg n=4. The "*" indicates that values are significantly different from
control, as determined by a student's t-test (p<0.05).

42

I
I

~

~

-------------------------------------------

*

3000

Q.

::::: 2000
0
'-:!'

6

1000

0,-t-'0

--,--

~

5

25

Tolfenamic acid (mg/kg)

43

50

Figure 13. AP ( 1-42) levels in the cerebral cortex of mice treated with various
doses of tolfenamic acid. Animals were 3 months at the beginning of the study.
They were given one of the following doses of tolfenamic acid 0, 1, 5, 25, 50
mg/kg. The drug was administered daily by oral gavage for 15 days. AP (1-42)
levels were measured by an ELISA assay according to the procedures illustrated
in the methods section. Values shown are the mean ± SEM. The number of
animals in each group: control n=3; I mg/kg n=4; 5 mg/kg n=3; 25 mg/kg n=4;
and 50 mg/kg n=5. The " *" indicates that values are significantly different from
control, as determined by a student's t-test (p<0.05).
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Table 1. A Summary of the effect of daily dosing with various doses of
tolfenamic acid on SP I, APP and A~. Animals' age was 3 months at the
beginning of the study. Animals were given one of the following doses of
tolfenamic acid 0, I, 5, 25, or 50 mg/kg, daily for I 5 days. Protein changes are
expressed as percentage change from controls.
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Dose
_im_g_/kg)

1
5
25
50

SPl
No
chan__g_e

-57.65%
No
chan__g_e
No
chan__g_e

APP

AP (1-40)

AP (1-42)

No change

-24.32%

-32.81%

-18.52%

-14.27%

-68.19%

No change

-25.29%

-32.96%

No change

-21.61 %

-29.54%

II
I
I
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Figure 14. Temporal changes in AP (l-40) levels in the cerebral cortex of mice
treated with tolfenamic acid. Animals' were 3 months of age at the beginning of
the study. Vehicle or 5 mg/kg tolfenamic acid were administered daily, and
animals were sacrificed at days 4, 8, and 16 after the beginning of the study. AP
( l-40) levels were measured by an ELISA assay as illustrated in the methods
section. Results expressed are the mean ± SEM. The number of animals in each
group, day 4 control n=4, treatment n=5 ; day 8 control n=4, treatment n=5; day 16
control n=3, treatment n=4. (p=0.06) according to student' s t-test, at day 16.
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Figure 15. Temporal changes in AP (1-42) levels in the cerebral cortex of mice
treated with tolfenamic acid. Animals' were 3 months at the beginning of the
study. Vehicle or 5 mg/kg tolfenamic acid were administered daily, and animals

I

were sacrificed at days 4, 8, and 16 after the beginning of the study. AP (l-42)

ii

levels were measured using an ELISA assay as illustrated in the methods section.
Values shown are the mean± SEM. The number of animals in each group, day 4
control n=4, treatment n=5; day 8 control n=4, treatment n=5; day 16 control n=3,
treatment n=3. The "*" indicates that values are significantly different from
control, as determined by a student's t-test (p<0.05).
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4.0 Discussion

Alzheimer' s disease is a neurodegenerative disorder causing progressive memory
depreciation until death. While the exact cause remains unknown, no disease
modi fy ing drug is available, and all existing medications only target the
symptoms. The presence of AP plaques and tau neurofibrillary tangles within the
cerebral cortex and hippocampal regions of the brain are the two major known
characteristics of the disease. AP is the product of the sequential cleavage of APP
by the enzymes P-secretase and y-secretase. Since the amyloid hypothesis has
closely linked these proteins with the pathology of AD (Hardy and Selkoe, 2002),
AP and other elements involved in its production have been targets for possible
therapeutic interventions.

The transcription factor Sp I has been linked to the pathology of AD. It is
invo lved in regulating the APP gene as well as BACE l (Christensen et al. , 2004;
Docagne et al., 2004; Basha et al. , 2005 ; Santpere et al., 2006). Therefore, any
process that impacts Sp l is likely to have an effect on APP levels as well as its
downstream products. Tolfenamic acid was shown to inhibit pancreatic tumors
growth by promoting the degradation of the transcription factors Sp 1, Sp3 , and
Sp4, and suppressing VEGF mRNA and protein expression (Abdelrahim et al. ,
2006). Thus, tolfenamic acid is likely to lower APP levels in the brain.
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In our studies, tolfenamic acid demonstrated a time dependent effect on APP and
A~

levels within certain doses; these are major pathological mediators in AD

according to the amyloid hypothesis. These effects were accompanied by a
correlated drop in the levels of the transcription factor SP 1 at certain doses. Those
results were first observed in a pilot trial in male mice where APP levels were
lowered by about 50% (Fig. 3A), and

A~

levels by 18% (Fig. 4). SPl protein

bands also were of lower intensity in the treated group than the control (Fig. 3B).

APP levels also were lower in male guinea pigs following tolfenamic acid
treatment (Fig. 5); however, the reduction in APP was less than that seen in mice.
Furthermore,

A~

(1-42) levels were mitigated but not significantly (Fig. 6). This

is more likely due to the small sample number used in this study. The findings in
guinea pigs demonstrate that the effects of tolfenamic acid on APP are not
species-specific.

In female mice, the same reduction levels were achieved after 28 days of alternate
day dosing (Fig. 7). This indicated that the effects of tolfenamic acid are not
gender-specific and appear to follow the same dose and time course requirements.
The relationship between AD and gender has been disputed as some studies
concluded that AD is indifferent to gender, while others argued that there was a
higher risk in women for developing AD (Barnes et. al., 2005). Our studies show
that tolfenamic acid had a similar effect on APP in male and female C57BL/6
mice.
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While alternate day dosing was selected in pilot trials to identify the time and
dose ranges where tolfenamic acid effects can be observed, a more accurate
determination can be achieved by daily dosing. Daily administration of tolfenamic
acid resulted in a reduction in all three endpoints namely APP, SP 1, and AP at
certain doses within 16 days (Table 1). The daily dosing time course was
consistent with previous alternate day dosing as the time was cut in half in daily
dosing.

The delay in the observed reduction of APP and AP levels in animals strongly
suggests that the lowering of these AD-related proteins is achieved through
interruption of processes associated with gene expression and regulation (Fig 8,
10, 14, 15). In pancreatic tumors, Spl inhibition was masked following treatment
with proteasome inhibitor, proposing that tolfenamic acid degradation of Sp 1 is
mediated by a proteasome (Abdelrahim et al., 2006). Such degradation would
deplete a cell from SP 1 reserves, and over time, less APP expression would be
expected due to a decreased pool of SPl. Likewise, the fact that AP levels take
weeks to exhibit a decline, suggests that the lowering of this peptide is linked to
the proteolytic elimination of SP 1 and lowered transcriptional activation of APP.

Although the temporal condition of lowering these intermediates was relative to
the dosing schedule, the effective dose range was very different. While higher
doses of 10, 25 mg had an effect on alternate day dosing, the effects of daily
dosing were only seen at 5 mg for APP and 5-10 mg for SP1. It is not clear why
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the dose range was narrowed following daily dosing, but this maybe related to the
half-life of the drug. In daily dosing a residual amount of the drug appears to
persist that saturates the system and renders higher doses ineffective, while in
alternate day dosing, the drug maybe washed out of the system before the next
dose is administered. In any event, the lower sensitivity is greatly advantageous
from a therapeutic perspective.

The expression of the APP gene is regulated by Sp I (Basha et al., 2005). In the
daily dosing study, it appeared that a 50% reduction in SP 1 levels had to be
achieved before any lowering of APP could be detected. This suggests that the
pools of SPl have to be reduced in half through tolfenamic acid induced
degradation at a rate that overwhelms SPl synthesis. Tolfenamic acid thus acts to
disrupt the balance between the de novo synthesis of APP and its degradation.

While a narrowing of the dose range was observed relative to SPl and APP, AP
levels on the other hand were lowered at daily doses tested from 1-50 mg/kg (Fig.
12, 13). While both AP (1-40) and (1-42) were lowered, there was a greater
lowering of AP (1-42) at the 5 mg dose. This is the dose where parallel reductions
were seen in both SPl and APP. This leads to the conclusion that the effects on
AP at the dose range of 1-10 mg is related to SPl and APP, while the lowering of
AP at higher dose may be associated with other mechanisms.
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The lowering of AP (1-42) is highly relevant because the 42 amino acid-long AP
is considered more aggressive than the other forms, and resulted in more rapid
aggregations in solutions with AP of varying sequences (Snyder et al., 1994;
Naslund et al., 2000). In solution, AP (1-40) aggregates were found to inhibit the
aggregation of AP (1-42) (Snyder et al. , 1994). The greater AP (1-42) decline
compared to AP (1-40) following the 5 mg/kg dose of tolfenamic acid suggests
that in vivo AP production might be shifted more towards the AP (1-40) fragment.

It is not clear why at higher doses the drug did not affect Sp 1 and APP while AP
was still lowered. A possible explanation could be that at higher doses the drug
was aggregating, and thus was trapped in tissue before it could get into the brain
in a concentration sufficient to cause Sp 1 and APP decline, in that case, cerebral
cortex AP lowering could be explained by the tolfenamic acid triggered peripheral
decline in AP acting as an AP sink from central compartments. This can be tested
by studying the effects of the drug on Sp 1, APP, and AP in peripheral tissue.

The pharmacokinetics of the drug could also play a role in the narrowing of the
dosage range where effects are observed on Sp 1, APP and Ap. The elimination
half-life of the drug from plasma was about 2.5 hours with 60 % bioavailability
and 99.7% protein binding (Pentikainen et al., I 981; Sidhu et al., 2006). However,
the terminal clearance half-life of tolfenamic acid metabolites was as long as 19
hours (Pentikainen et al. , 1984). Unpublished studies from our lab have confirmed
that tolfenamic acid is available in the brain following oral or intramuscular
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administration, still it is not yet proven whether the effects observed on Sp 1, APP,
and AP are due to the parent compound or one of its metabolites. Nevertheless,
one would expect the metabolites to be more polar and larger in size, and thus
with lesser brain penetration potential than the parent drug; however, it is possible
that some derivative of tofenamic acid is responsible for these effects.

Furthermore, considering the fact that the rate and the degree of tolfenamic acid
absorption and elimination are not dose dependent (Pentikainen et al. , 1981 ),
higher doses of tolfenamic acid administered daily could have resulted in the
depletion of the target proteasome that degrades Sp 1, and thus at such doses of
tolfenamic acid, the target could have been used up, this would affect the response
at the pharmacodynamic level. On the other hand, every other day administration
might have allowed more time during which the body is drug free and the targets
can be regenerated to be available for the next dosage. Nevertheless, doses as low
as 5 mg/kg would still be more favorable, since they would be associated with
fewer NSAID's related gastrointestinal side effects, and they are close to the doses
approved for migraine headaches in humans, and pain control in veterinary
medicine .
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5.0 Conclusion

These studies were primarily conducted to examine whether or not tolfenamic
acid is capable of altering AP and APP protein levels, as important pathological
intermediates in neurodegeneration and AD. Additionally, the studies aimed at
finding the effective dose and time range at which such outcomes occur.
Tolfenamic acid was able to lower the levels of cerebral SP I, APP, and AP with
certain doses in wild type male mice. Temporal studies showed that the decline in
APP and AP was time dependent. These effects seemed to be mediated through
SP 1 degradation at a lower dose of the drug, i.e. 5 mg/kg administered daily. At
higher doses AP lowering does not appear to be associated with the decrease in
SPl decrease suggesting that there is an alternate mechanism underlying the AP
change. In addition, tolfenamic acid lowered APP in the cerebral cortex of female
mice, and Hartley guinea pigs. Accordingly, tolfenamic acid could be beneficial
for AD by targeting essential pathological mediators within the disease process.
Further behavioral tests in AD animal models are necessary to determine the
relationship between the molecular changes and cognitive improvement.
Moreover, the connection between AP lowering and plaque burden needs to be
examined. More research is needed in order to reveal the exact mechanism by
which tolfenamic acid affects AD related proteins and the consequential effect on
behavior and plaque pathology.
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